{"name":"Yassin Abdelghaffar Charity Center for Liver Disease and Research","slug":"yassin-abdelghaffar-charity-center-for-liver-disease-and-research","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Combined Therapy SOF and DCV","genericName":"Combined Therapy SOF and DCV","slug":"combined-therapy-sof-and-dcv","indication":"Chronic hepatitis C virus infection (genotype-dependent)","status":"phase_3"},{"name":"Combined therapy LDV and SOF","genericName":"Combined therapy LDV and SOF","slug":"combined-therapy-ldv-and-sof","indication":"Chronic hepatitis C virus infection (genotypes 1-6)","status":"marketed"}]}],"pipeline":[{"name":"Combined Therapy SOF and DCV","genericName":"Combined Therapy SOF and DCV","slug":"combined-therapy-sof-and-dcv","phase":"phase_3","mechanism":"This combination therapy uses sofosbuvir (a nucleotide polymerase inhibitor) and daclatasvir (an NS5A inhibitor) to block hepatitis C virus replication through dual inhibition of viral enzymes.","indications":["Chronic hepatitis C virus infection (genotype-dependent)"],"catalyst":""},{"name":"Combined therapy LDV and SOF","genericName":"Combined therapy LDV and SOF","slug":"combined-therapy-ldv-and-sof","phase":"marketed","mechanism":"LDV (ledipasvir) and SOF (sofosbuvir) are direct-acting antivirals that inhibit hepatitis C virus NS5A and NS5B polymerase, respectively, blocking viral replication.","indications":["Chronic hepatitis C virus infection (genotypes 1-6)"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":1,"marketed":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}